Minimal Residual Disease Testing Market is Expected to Reach $2.3 Billion
"Asia Pacific MRD testing market is expected to be worth USD 554.1 million by 2029, growing at CAGR of 13.6% during the forecast period."
The global minimal residual disease testing market, valued at US$1.27 billion in 2023, is forecasted to grow at a robust CAGR of 12.2%, reaching US$1.43 billion in 2024 and an impressive US$2.55 billion by 2029
In the near future, the Minimal Residual Disease (MRD) testing industry is poised to experience remarkable growth and transformative advancements. As precision medicine gains momentum, MRD testing will become an integral component in cancer management and treatment evaluation. Technological innovations will enhance the sensitivity and specificity of MRD detection methods, enabling earlier and more accurate detection of residual cancer cells post-treatment. Next-generation sequencing, liquid biopsy approaches, and innovative biomarker identification will revolutionize the landscape, allowing for non-invasive and real-time monitoring of MRD. Moreover, the integration of artificial intelligence and machine learning algorithms will streamline data analysis and interpretation, empowering clinicians to make data-driven decisions tailored to individual patient needs. This amalgamation of cutting-edge technologies and personalized medicine will undoubtedly revolutionize the MRD testing industry, facilitating more effective cancer therapies and ultimately improving patient outcomes.
Minimal Residual Disease Testing market in terms of revenue was estimated to be worth $1.2 Billion in 2022 and is poised to reach $2.3 Billion by 2027, growing at a CAGR of 14.0% from 2022 to 2027 according to a latest report published by MarketsandMarkets™. Factors such as the rising prevalence of cancer and hematological malignancies, growing initiatives undertaken by government bodies to create awareness about cancer, and increasing collaborations are factors driving the growth of the global minimal residual disease testing market.
Minimal Residual Disease Testing market major players covered in the report, such as:
Labcorp Inc. (US)
F. Hoffmann-La Roche Ltd. (Switzerland)
Guardant Health (US)
Sysmex Corporation (Japan)
NeoGenomics Laboratories, Inc. (US)
Adaptive Biotechnologies Corporation (US)
ArcherDX, Inc. (US)
Asuragen Inc. (US)
Arup Laboratories Inc. (US)
Bio-Rad Laboratories, Inc. (US)
Cergentis B.V. (Netherlands)
Molecular MD (ICON plc) (Ireland)
Invivoscribe, Inc. (US)
Mission Bio, Inc. (US)
Natera, Inc. (US)
Opko Health, Inc. (US)
Quest Diagnostics (US)
Genetron Health (China)
and Among Others
Buy Minimal Residual Disease Testing Industry Report (179 Pages PDF with Insightful Charts, Tables, and Figures): https://www.marketsandmarkets.com/Purchase/purchase_reportNew.asp?id=215386038
This report categorizes the minimal residual disease testing market into the following segments and subsegments:
By Technology
Flow Cytometry
Polymerase Chain Reaction (PCR)
Next-Generation Sequencing (NGS)
Other Technologies
By Application
Hematological Malignancies
Leukemia
Lymphoma
Solid Tumors
Other Applications
By End User
Hospitals and Specialty Clinics
Diagnostic Laboratories
Academic & Research Institutes
Other End Users
By Region
North America
US
Canada
Europe
Germany
UK
France
Italy
Spain
Rest of Europe
Asia Pacific
China
Japan
India
Rest of Asia Pacific
Latin America
Middle East & Africa
The key stakeholders in the Minimal Residual Disease Testing market include:
Healthcare Providers: Oncologists, hematologists, and other healthcare professionals who order MRD testing for cancer patients as part of their treatment monitoring and management.
Diagnostic Laboratories: Clinical and specialized laboratories that conduct MRD testing, process samples, and provide test results to healthcare providers and patients.
Pharmaceutical Companies: Companies involved in developing and producing cancer therapies and treatments, as MRD testing plays a crucial role in clinical trials and assessing treatment efficacy.
Research Institutions: Academic and private research institutions that contribute to the advancement of MRD testing technologies and methodologies.
Patients: Individuals diagnosed with cancer who undergo MRD testing to assess treatment response and potential disease recurrence.
Regulatory Authorities: Government bodies and agencies responsible for overseeing and approving MRD testing technologies, ensuring their safety and efficacy.
Insurance Providers: Health insurance companies that may cover or reimburse the cost of MRD testing for eligible patients.
Technology Providers: Companies offering MRD testing platforms, equipment, and software for laboratories and healthcare facilities.
Patient Advocacy Groups: Organizations representing patients with cancer, advocating for improved access to and affordability of MRD testing and related treatments.
Healthcare Administrators: Hospital and clinic administrators who manage the integration of MRD testing into the broader healthcare system.
As the MRD testing market continues to expand, collaboration and coordination among these stakeholders will be vital to drive innovation, improve patient outcomes, and ensure the effective implementation of MRD testing in cancer care.
Frequently Asked Questions (FAQs) of Minimal Residual Disease Testing Market:
What are the recent trends affecting the minimal residual disease testing market?Ans. Recent trends affecting the minimal residual disease testing market are the rising incidence and prevalence of hematological malignancies and cancer, cancer awareness initiatives undertaken by global health organizations.
What are the major application areas of minimal residual disease testing market?Ans. Based on application, the minimal residual disease testing market is segmented into hematological malignancies, solid tumors and other applications.
Who are the key players in the minimal residual disease testing market?Ans. The key players operating in this market are Labcorp Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), Guardant Health (US), Sysmex Corporation (Japan), NeoGenomics Laboratories, Inc. (US), Adaptive Biotechnologies Corporation (US), ArcherDX, Inc. (US), Asuragen Inc. (US), Arup Laboratories Inc. (US), Bio-Rad Laboratories, Inc. (US), Cergentis B.V. (Netherlands), Molecular MD (ICON plc) (Ireland), Invivoscribe, Inc. (US), Mission Bio, Inc. (US), Natera, Inc. (US), Opko Health, Inc. (US), Quest Diagnostics (US), and Genetron Health (China), among others.Who are the major end users of minimal residual disease testing products & services?Based on end user, the minimal residual disease testing market has been segmented into reference laboratories, hospitals and physician laboratories, academic & research centers, and other end users.
Which region is lucrative for the minimal residual disease testing market?Ans. Like China, Japan, and India, the emerging economies in the Asia Pacific region will be the lucrative markets for minimal residual disease testing market.
Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=215386038
Report Objectives:
To define, describe, segment, and forecast the global minimal residual disease testing market by technology, application, end user, and region
To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall minimal residual disease testing market
To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
To forecast the size of the market segments with respect to five regions, namely, North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
To profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies
To track and analyze company developments such as product launches, agreements, partnerships, and acquisitions in the minimal residual disease testing market
To benchmark players within the market using the proprietary "Competitive Leadership Mapping" framework, which analyzes market players on various parameters within the broad categories of business and product strategy
Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email: Send Email
Phone: 18886006441
Address: 1615 South Congress Ave. Suite 103, Delray Beach, FL 33445
City: Florida
State: Florida
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/minimal-residual-disease-testing-market-215386038.html
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
an hour ago
- Cision Canada
Nuveen Australian Real Estate Debt Strategy Reaches A$650 Million with CPP Investments Commitment
SYDNEY, /CNW/ - Nuveen, one of the largest asset managers globally with over US$1.3 trillion AUM*, has reached second close of its commingled Australian commercial real estate debt strategy with commitments of over A$650 million. Canada Pension Plan Investment Board (CPP Investments), through its subsidiary CPPIB Credit Investments Inc., invested A$300 million, joining Teachers Insurance and Annuity Association of America (TIAA) and Temasek as strategic partners of Nuveen for this strategy. Total AUM are expected to exceed A$1 billion including capital approved for co-investments. The strategy is already more than 40% deployed via committed loan investments focusing on institutional senior and junior loans secured by prime real estate in Australia. Preferred sectors for the strategy are industrial / logistics and residential, with a selective approach to retail, office and alternatives across major cities in Australia. The strategy leverages both Nuveen Real Estate's global debt platform, which currently has over 55 dedicated specialists, and the team of more than 60 at Nuveen Real Estate in Asia. The strategy is led by Dugald Marr, Nuveen's Head of Debt Australia and New Zealand, and the support of an experienced team with a long track record of originating and structuring high-quality loan investments in this market. Investments are also aligned to Nuveen Real Estate's comprehensive responsible investment processes and ESG factor analysis. This includes waste reduction and energy consumption, climate risk analysis and social aspects with the ability to structure Green Loans or Sustainable Linked Loans where applicable to incentivise ESG targets on behalf of clients. The investment comes at a time when Australian commercial real estate debt offers the potential for a compelling blend of stability, attractive yields, and strong collateral protection, all of which are increasingly important to investors concerned about global volatility. Australia's mature market, supported by robust economic foundations, strict regulatory requirements for banks and the need for more alternative capital sources provides a good foundation for long-term investment in this space. The strategy will continue to focus on repeat institutional borrowers, conservative lending parameters and prime assets in sectors that benefit most from Australia's high population growth and limited supply. Andrew Kleinig, Head of Australia and the Global Client Group for South East Asia at Nuveen, said: "This is another milestone for the strategy. With CPP Investments' commitment, we will continue our focus on strategic, in-depth partnerships with the highest calibre of investors. We are excited to work with a like-minded partner who also shares a high conviction on the asset class. CPP Investments has provided significant value-add as a strategic investor, ensuring long-term success and growth of the partnership. It showcases Nuveen's pedigree in real estate investment and our ability to bring regionally tailored solutions across both equity and debt platforms. We believe Nuveen's offering across real assets more broadly is well-positioned to help clients across Asia navigate volatility alongside managing their responsible investment goals." Raymond Chan, Managing Director & Head of APAC Credit at CPP Investments, said: "Australia is one of our key markets in Asia Pacific and this transaction marks an important milestone for our credit strategy in the region. The investment builds upon our extensive market research and insights from our successful investments in Australia. Leveraging Nuveen's strong local network and capabilities, this partnership enables us to tap into attractive real estate debt investments in Australia and further augment our credit program in the region. These opportunities offer stability and attractive yields amid global volatility, contributing to long-term returns for the CPP Fund." *Top 20 largest global asset manager based on Pensions & Investments, 12 Jun 2023. Rankings based on total worldwide assets as of 31 Dec 2022 reported by each responding asset manager, with 434 firms responding; updated annually. TIAA is the parent company of Nuveen. About Nuveen Nuveen, the investment manager of TIAA, offers a comprehensive range of outcome-focused investment solutions designed to secure the long-term financial goals of institutional and individual investors. Nuveen has $1.3 trillion in assets under management as of 30 September 2024 and operations in 27 countries. Its investment specialists offer deep expertise across a comprehensive range of traditional and alternative investments through a wide array of vehicles and customized strategies. For more information, please visit Nuveen Real Estate is one of the largest investment managers in the world with US$142 billion of assets under management. Managing a suite of funds and mandates, across both public and private investments, and spanning both debt and equity across diverse geographies and investment styles, we provide access to every aspect of real estate investing. With over 90 years of real estate investing experience and more than 770 employees* located across 30+ cities throughout the United States, Europe and Asia Pacific, the platform offers global reach with deep sector expertise, providing investors access to high quality investments across the private real estate investment landscape. For further information, please visit us at *Includes 360+ real estate investment professionals, supported by a further 411 Nuveen employees. Source: Nuveen, 31 March 2025. About CPP Investments Canada Pension Plan Investment Board (CPP Investments™) is a professional investment management organization that manages the Fund in the best interest of the more than 22 million contributors and beneficiaries of the Canada Pension Plan. In order to build diversified portfolios of assets, investments are made around the world in public equities, private equities, real estate, infrastructure and fixed income. Headquartered in Toronto, with offices in Hong Kong, London, Mumbai, New York City, San Francisco, São Paulo and Sydney, CPP Investments is governed and managed independently of the Canada Pension Plan and at arm's length from governments. At March 31, 2025, the Fund totalled C$714.4 billion. For more information, please visit or follow us on LinkedIn, Instagram or on X @CPPInvestments.
Cision Canada
3 hours ago
- Cision Canada
Petro-Victory Energy Corp. Announces Short Term Loans
/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF U.S. SECURITIES LAWS/ DALLAS, June 11, 2025 /CNW/ - Petro-Victory Energy Corp. (TSXV: VRY) (" Petro-Victory" or the " Company") announces that it has borrowed an aggregate of US$350,000 (the " Loans") and issued unsecured promissory notes to Thomas Cooper, a director of the Company, and to an arm's length third party (collectively, the " Lenders"). The Loans have a term of one year and bear interest at an annual rate of 14% per annum until maturity and 18% per annum thereafter. The Lenders will be issued an aggregate of 685,350 bonus warrants (the " Warrants") in connection with the Loans, with each Warrant being exercisable at CAD$0.70 per common share on or before June 2, 2026. The Loans and issuance of Warrants remain subject to TSX Venture Exchange (" TSXV") final acceptance. The Loan from Thomas Cooper in the aggregate amount of US$175,000 and the issuance of 342,675 Warrants in connection therewith each constituted a "related party transaction" under Multilateral Instrument 61-101 - Protection of Minority Security Holders in Special Transactions ("MI 61-101") as Mr. Copper is a related party (as defined in MI 61-101) of the Company. The Company relied on the exemptions from the formal valuation and minority shareholder approval requirements of MI 61-101 contained in Sections 5.5(a) and 5.7(1)(a) of MI 61-101 in respect of related party matters, as the Company is listed on the TSXV and neither the fair market value (as determined under MI 61-101) of the subject matter of, nor the fair market value of the consideration for, the transaction, insofar as it involves the related parties, exceeded 25% of the Company's market capitalization (as determined under MI 61-101). About Petro-Victory Energy Corp. Petro-Victory Energy Corp. is an oil and gas company engaged in the acquisition, development, and production of crude oil and natural gas in Brazil. The total portfolio under management includes 49 concession contracts with 276,755 acres, net to Petro-Victory plus an additional 6 concessions and 19,074 acres owned jointly with BlueOak. Through disciplined investments in high-impact, low-risk assets, Petro-Victory is focused on delivering sustainable shareholder value. The Company's common shares trade on the TSX Venture Exchange under the ticker symbol VRY. Cautionary Note Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release. This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities, in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), or any state securities laws and may not be offered or sold within the United States unless an exemption from such registration is available. In the interest of providing Petro-Victory's shareholders and potential investors with information regarding Petro-Victory's future plans and operations, certain statements in this press release are "forward-looking statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995 and "forward-looking information" within the meaning of applicable Canadian securities legislation (collectively, " forward-looking statements"). In some cases, forward-looking statements can be identified by terminology such as "anticipate," "believe," "continue," "could," "estimate," "expect," "forecast," "intend," "may," "objective," "ongoing," "outlook," "potential," "project," "plan," "should," "target," "would," "will" or similar words suggesting future outcomes, events or performance. The forward-looking statements contained in this press release speak only as of the date thereof and are expressly qualified by this cautionary statement. Specifically, this press release contains forward-looking statements relating to, but not limited to, TSXV approval for the Loan and Warrants. These forward-looking statements are based on certain key assumptions regarding, among other things, the receipt of TSXV approval for the Loan and Warrants. Readers are cautioned that such assumptions, although considered reasonable by Petro-Victory at the time of preparation, may prove to be incorrect. Actual results achieved will vary from the information provided herein as a result of numerous known and unknown risks and uncertainties and other factors. The above summary of assumptions and risks related to forward-looking statements in this press release has been provided in order to provide shareholders and potential investors with a more complete perspective on Petro-Victory's current and future operations and such information may not be appropriate for other purposes. There is no representation by Petro-Victory that actual results achieved will be the same in whole or in part as those referenced in the forward-looking statements and Petro-Victory does not undertake any obligation to update publicly or to revise any of the included forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by applicable securities law. SOURCE Petro-Victory Energy Corp.
Cision Canada
4 hours ago
- Cision Canada
Argo Named to Fast Company's 2025 World Changing Ideas List for Smart Routing™ Transit Platform
Vertically integrated transit solution recognized for transforming urban mobility and creating more equitable, sustainable cities TORONTO, June 11, 2025 /CNW/ - Argo Corporation (TSXV: ARGH) (OTCQX: ARGHF) (" Argo" or the " Company"), a leader in next-generation transit solutions, announced today that it was named a winner of Fast Company's 2025 World Changing Ideas Awards. This annual recognition honours bold and transformative efforts that tackle the world's most pressing challenges. Argo was recognized for its Smart Routing™ transit platform that aims to revolutionize how cities move people while addressing critical climate, equity, and accessibility challenges. Fast Company selected Argo as a winner from over 1500 initiatives worldwide, highlighting the Company's innovative approach to solving one of urbanization's greatest challenges: providing effective mobility for billions of people in rapidly growing cities while reducing emissions and improving quality of life. "The World Changing Ideas Awards have always been about showcasing the art of the possible," says Fast Company editor-in-chief Brendan Vaughan. "We're proud to recognize the organizations and leaders that are making meaningful progress on the biggest issues of our time." "We launched Argo one year ago today with a vision to solve one of the world's most urgent challenges: modernizing public transit so it's as convenient as driving, but accessible to everyone," said Praveen Arichandran, CEO and co-founder of Argo. "We're proud to be showcasing Canadian innovation on a global stage, starting in the town of Bradford West Gwillimbury and soon expanding to Brampton. This recognition by Fast Company affirms our belief that the next generation of globally ambitious companies can be built right here in Ontario." In conjunction with this award, Arichandran was also named to Fast Company's Impact Council, a collective of the most innovative leaders in business. About Fast Company Fast Company is the only media brand fully dedicated to the vital intersection of business, innovation, and design, engaging the most influential leaders, companies, and thinkers on the future of business. Headquartered in New York City, Fast Company is published by Mansueto Ventures LLC, along with our sister publication Inc., and can be found online at About Argo Founded in June 2024, Argo delivers the world's first fully vertically integrated transit system, combining proprietary Argo X1 electric vehicles, Smart Routing™ technology, and comprehensive operational management in a single end-to-end solution. By integrating every aspect of the transit experience, Argo enables municipalities to enhance their existing transit networks with dynamically optimized services that aim to deliver substantially better efficiency, coverage, and rider satisfaction, all while maintaining standard public transit pricing. The company launched Argo School in September 2024 and began its first municipal deployment in Bradford West Gwillimbury in early 2025. Learn more at Praveen Arichandran, CEO Argo Corporation (800) 575-7051 Forward-Looking Information This news release includes certain forward-looking statements as well as management's objectives, strategies, beliefs and intentions. Forward-looking statements are frequently identified by such words as "may", "will", "plan", "expect", "anticipate", "estimate", "intend" and similar words referring to future events and results. Forward-looking statements are based on the current opinions and expectations of management. All forward-looking information is inherently uncertain and subject to a variety of assumptions, risks and uncertainties, as described in more detail in the Company's securities filings available at Actual events or results may differ materially from those projected in the forward-looking statements and we caution against placing undue reliance thereon. We assume no obligation to revise or update these forward-looking statements except as required by applicable law.
